About S-phase kinase-associated protein 2
S-phase kinase-associated protein 2 (SKP2) is a protein
from Homo sapiens identified by UniProt accession
Q13309, 424 residues long.
MolForge cross-references it against 0 known binders and
262 disease associations.
Target properties
| Protein name | S-phase kinase-associated protein 2 |
| UniProt accession | Q13309 |
| Gene | SKP2 |
| Organism | Homo sapiens |
| Length | 424 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (262)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- mean corpuscular volume · score 0.49
- multiple sclerosis · score 0.43
- Alzheimer disease · score 0.43
- Parkinson disease · score 0.43
- lysosomal storage disease · score 0.43
- Red cell distribution width · score 0.43
- mean corpuscular hemoglobin concentration · score 0.39
- appendicular lean mass · score 0.39
- mean reticulocyte volume · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13309-F1 | alphafold | PREDICTED | 82.13 | — |
Amino-acid sequence (424 residues)
MHRKHLQEIP DLSSNVATSF TWGWDSSKTS ELLSGMGVSA LEKEEPDSEN IPQELLSNLG HPESPPRKRL KSKGSDKDFV IVRRPKLNRE NFPGVSWDSL PDELLLGIFS CLCLPELLKV SGVCKRWYRL ASDESLWQTL DLTGKNLHPD VTGRLLSQGV IAFRCPRSFM DQPLAEHFSP FRVQHMDLSN SVIEVSTLHG ILSQCSKLQN LSLEGLRLSD PIVNTLAKNS NLVRLNLSGC SGFSEFALQT LLSSCSRLDE LNLSWCFDFT EKHVQVAVAH VSETITQLNL SGYRKNLQKS DLSTLVRRCP NLVHLDLSDS VMLKNDCFQE FFQLNYLQHL SLSRCYDIIP ETLLELGEIP TLKTLQVFGI VPDGTLQLLK EALPHLQINC SHFTTIARPT IGNKKNQEIW GIKCRLTLQK PSCL
Explore S-phase kinase-associated protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets